Blood­ied Cel­gene posts promis­ing ozan­i­mod PhI­II MS da­ta, but is it re­al­ly a $6 bil­lion drug?

Cel­gene pumped out its Phase III da­ta on its block­buster con­tender ozan­i­mod over the week­end, of­fer­ing some en­cour­ag­ing com­par­isons with Avonex in treat­ing pa­tients with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER